News | August 19, 2025
Pfizer’s sickle cell disease candidate fails Phase III trial
Inclacumab was generally well tolerated in THRIVE-131
Inclacumab was generally well tolerated in THRIVE-131
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
Pfizer's decision is based on the totality of clinical data
This new medication eliminates the need for cold storage, making it more accessible and affordable for SCD patients across India
The National Sickle Cell Anaemia Elimination Mission was launched on 1st July 2023 at Shahdol, Madhya Pradesh
Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
A First of its Kind Initiative in Mahbubnagar District for Medical Officers, ANM, Anganwadi workers for prevention of Thalassemia and Sickle Cell anemia as part of Antenatal screening of pregnant women project
Thalassemia and Sickle Cell Society (TSCS) always stands forefront in providing blood transfusion free of cost for Thalassemia Blood disorders patients
TSCS appeals to the Govt. of Telangana to release a G.O for mandatory antenatal test - HbA2 for every pregnant woman to help prevent the birth of Thalassemia Major Children for the well-being of their family & Telangana State
Subscribe To Our Newsletter & Stay Updated
